MOR-212

N/A

Report date: 2026/03/19 16:53:24

Base Information

Drug NameMOR-212

Drug Alias Nameanti-CD3/anti-CD20 bispecific T-cell engager (MorphoSys)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsImmunostimulantsT lymphocytes stimulants +[4]

TargetsB-lymphocyte antigen CD20T cell surface glycoprotein CD3

Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMorphosys Ag

China Registration ClassN/A

Develop Information

Active CompaniesMorphosys Ag

Inactive CompaniesN/A

Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A